SYLENTIS: Funding, Investors & Team (Sep 2026)
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company
SYLENTIS has raised $24.7M across 1 funding round on record, the most recent an undisclosed round of $24.7M announced in Jul 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SYLENTIS Company Profile and Key Stats
Latest funding round on record: Jul 2025.
SYLENTIS Funding Rounds
SYLENTIS Founders and Leadership Team
No contact details are on record for this team yet.
SYLENTIS Funding Compared to Other Biotechnology Startups
SYLENTIS' latest round of $24.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SYLENTIS in Biotechnology and Madrid
Companies Similar to SYLENTIS
Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of…
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
SYLENTIS Funding FAQs
What does SYLENTIS do?
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company
How much funding has SYLENTIS raised?
SYLENTIS has raised $24.7M across 1 round on record. The most recent is an undisclosed round of $24.7M announced in Jul 2025.
When did SYLENTIS last raise funding?
SYLENTIS' most recent funding round on record is an undisclosed round of $24.7M, announced in Jul 2025.
Who founded SYLENTIS?
FundedIQ lists Jose Maria Fernandez Sousa Faro (Founder) at SYLENTIS.
Where is SYLENTIS headquartered?
SYLENTIS is based in Madrid, Spain.
How many employees does SYLENTIS have?
SYLENTIS is in the 51-100 employee band.
How does SYLENTIS' funding compare to other Biotechnology startups?
SYLENTIS' latest round of $24.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's SYLENTIS Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SYLENTIS is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.